TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank67
5Y CAGR-40.8%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

5Y CAGR
-40.8%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
TTM$1.49M-
2024$0.00-
2023$0.00-
2022$0.00-
2021$0.00-100.0%
2020$20.58M+117.9%
2019$9.44M-